- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Data Show Overall Response of 68 Percent in Patients with Relapsed or Refractory Disease
New Long-Term Study Suggests Lower Mortality in Alzheimer’s Patients Treated with Galantamine Versus Placebo
Significantly Lesser Cognitive Decline Also Seen in Treatment Group Compared to Placebo Group
Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings
Policy Aims to Support a Sustainable Supply of Medically Acceptable Generic Darunavir in Sub-Saharan Africa (SSA) and Least Developed Countries (LDC)
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Lilly and Merck are First to Join Janssen in this Pre-Competitive Initiative to Increase Efficiencies in Clinical Trials
Efficacy and Safety Data from Phase 2B Trials of Janssen’s Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Data from Post Hoc Analyses of the ASPIRE and PILLAR Studies in Patients with Metavir Scores of F3 and F4 Show Sustained Viral Response Compared to Placebo